

Peter Steinwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3150856/publications.pdf>

Version: 2024-02-01

12
papers

25
citations

2258059

3
h-index

2550090

3
g-index

12
all docs

12
docs citations

12
times ranked

68
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer, 2019, 19, 524. | 2.6 | 12 |
| 2 | TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 148-154. | 1.9 | 7 |
| 3 | Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report. Clinical Genitourinary Cancer, 2020, 18, e312-e314. | 1.9 | 6 |
| 4 | cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.. Journal of Clinical Oncology, 2018, 36, 256-256. | 1.6 | 0 |
| 5 | cfDNA TP53 mutations with treatment history and disease progression in metastatic CRPC.. Journal of Clinical Oncology, 2018, 36, 263-263. | 1.6 | 0 |
| 6 | Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.. Journal of Clinical Oncology, 2018, 36, 261-261. | 1.6 | 0 |
| 7 | Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 255-255. | 1.6 | 0 |
| 8 | Evaluation of circulating tumor DNA (ctDNA) with respect to germline alterations in metastatic castrate resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 254-254. | 1.6 | 0 |
| 9 | Aberrations in androgen receptor ctDNA varies by race in metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 247-247. | 1.6 | 0 |
| 10 | TP53 mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer mCRPC.. Journal of Clinical Oncology, 2019, 37, 249-249. | 1.6 | 0 |
| 11 | ctDNA and copy-number variant quantification in mCRPC at the time of progression.. Journal of Clinical Oncology, 2019, 37, 265-265. | 1.6 | 0 |
| 12 | Circulating tumor DNA (ctDNA) landscape in metastatic castrate-resistant prostate cancer patients with germline alterations.. Journal of Clinical Oncology, 2020, 38, 200-200. | 1.6 | 0 |